Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Up 23.0% in August

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 5,460,000 shares, a growth of 23.0% from the August 15th total of 4,440,000 shares. Based on an average daily trading volume, of 444,800 shares, the days-to-cover ratio is presently 12.3 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Vanguard Group Inc. raised its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 2.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,001,836 shares of the company’s stock after acquiring an additional 26,854 shares during the quarter. Vanguard Group Inc. owned about 3.59% of Reviva Pharmaceuticals worth $3,787,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 63.18% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Benchmark reiterated a “speculative buy” rating and issued a $17.00 target price on shares of Reviva Pharmaceuticals in a report on Monday, August 26th. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Reviva Pharmaceuticals in a research report on Thursday, July 11th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 16th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Reviva Pharmaceuticals Stock Performance

RVPH traded up $0.08 during midday trading on Friday, reaching $1.20. The company had a trading volume of 206,463 shares, compared to its average volume of 851,893. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $6.80. The business has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.98. The stock has a market cap of $33.50 million, a PE ratio of -0.75 and a beta of -0.10.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. On average, research analysts anticipate that Reviva Pharmaceuticals will post -0.98 earnings per share for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.